PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33754379-1	2021	Favipiravir is an anti-viral agent effective against several RNA viruses that is converted into an inactive oxidative metabolite (M1), mainly by aldehyde oxidase, in humans.	favipiravir	0-11	aldehyde oxidase 1	Homo sapiens	145-161
32338164-6	2021	The results show the effectiveness of Sofosbuvir, Ribavirin, Galidesivir, Remdesivir, Favipiravir, Cefuroxime, Tenofovir, and Hydroxychloroquine, in binding to SARS-CoV-2 RdRp.	favipiravir	86-97	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	171-175
34021797-4	2021	METHODS: The study enrolled pediatric patients aged under 18 years and confirmed as suffering from COVID-19 and multisystem inflammatory syndrome in children (MIS-C) with any degree of kidney injury, who were treated with favipiravir at the time of admission.	favipiravir	222-233	anti-Mullerian hormone	Homo sapiens	159-162
33992054-3	2022	The recent clinical trials on antiviral drugs highlighted some promising compounds such as umifenovir (haemagglutinin-mediated fusion inhibitor), remdesivir (RdRp nucleoside inhibitor), and favipiravir (RdRp Inhibitor).	favipiravir	190-201	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	203-207
34017865-6	2021	Methods: Atazanavir, remdesivir, ritonavir, lopinavir and favipiravir were docked to in silico models of the pore domain of hERG, derived from cryo-EM structures of hERG and the closely related EAG channel.	favipiravir	58-69	ETS transcription factor ERG	Homo sapiens	124-128
34017865-6	2021	Methods: Atazanavir, remdesivir, ritonavir, lopinavir and favipiravir were docked to in silico models of the pore domain of hERG, derived from cryo-EM structures of hERG and the closely related EAG channel.	favipiravir	58-69	ETS transcription factor ERG	Homo sapiens	165-169
33556871-4	2021	The present article provides an overview of these small-molecule therapeutics based on insights from medicinal chemistry research and focuses on RNA-dependent RNA polymerase (RdRp) inhibitors, such as the nucleoside analogues remdesivir, favipiravir and ribavirin.	favipiravir	238-249	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	175-179
33961695-3	2021	beta-D-N 4-hydroxycytidine (NHC, the initial metabolite of molnupiravir) is more than 100-fold more active than ribavirin or favipiravir against SARS-CoV-2, with antiviral activity correlated to the level of mutagenesis in virion RNA.	favipiravir	125-136	high mobility group nucleosomal binding domain 4	Homo sapiens	28-31
33754379-7	2021	This suggests that the roles of aldehyde oxidase in the hepatic metabolism of favipiravir extensively differ depending on species and sex, and this study will aid in the assessment of the anti-viral activities of favipiravir against novel and/or variant viruses.	favipiravir	78-89	aldehyde oxidase 1	Homo sapiens	32-48
33930706-10	2021	C-reactive protein decreased significantly after treatment in the favipiravir group (p = 0.016).	favipiravir	66-77	C-reactive protein	Homo sapiens	0-18
33693066-7	2021	In this study, we have screened a library of compounds, containing approved RdRp inhibitor drugs that were or in use to treat other viruses (favipiravir, sofosbuvir, ribavirin, lopinavir, tenofovir, ritonavir, galidesivir and remdesivir) and their structural analogues, in order to identify potential inhibitors of SARS-CoV-2 RdRp.	favipiravir	141-152	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	76-80
33685502-24	2021	Arm 2: Favipiravir + Lopinavir/ritonavir placebo Oral favipiravir at 1800mg twice daily on Day 1, followed by 400mg four (4) times daily from Day 2 to Day 7 PLUS lopinavir/ritonavir matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.	favipiravir	7-18	Jupiter microtubule associated homolog 1	Homo sapiens	0-5
33727943-8	2021	Results: The results show that all tested compounds of sumac provided good interaction with the main active site of SARS-CoV-2 Mpro, with better, lower molecular docking energy (kcal/mol) compared to the well-known drugs chloroquine and favipiravir (Avigan).	favipiravir	237-248	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	127-131
32786685-7	2020	The drug repurposing study revealed the high potential of noscapine and proximal binding to the Mpro enzyme in a comparative binding pattern analyzed with chloroquine, ribavirin, and favipiravir.	favipiravir	183-194	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	96-100
33347311-5	2021	The inhibitors of the virus entry to cells and RdRp, such as Arbidol, remdesivir, favipiravir, EIDD-2081, and ribavirin, are in clinical trials, while most of the protease inhibitors are mainly calculated by molecular docking technology, which needs in vivo and in vitro experiments to prove the effect for SARS-CoV-2.	favipiravir	82-93	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	47-51
33176880-11	2020	Favipiravir, chloroquine and hydroxychloroquine also showed some significant MPro inhibition.	favipiravir	0-11	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	77-81
33176643-8	2021	RESULTS: Nimbocinol (-7.6 Kcal/mol) and sage (-7.3 Kcal/mol) exhibited maximum BA against PLpro SARS-CoV-2 as evident from molecular docking study which was found to be even better than remdesivir (-6.1 Kcal/mol), chloroquine (-5.3 Kcal/mol) and favipiravir (-5.7 Kcal/mol).	favipiravir	246-257	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	90-95
33378989-2	2021	In theory, tocilizumab and favipiravir are considered to be reliable drugs for the treatment of COVID-19 with elevated IL-6.	favipiravir	27-38	interleukin 6	Homo sapiens	119-123
33251975-4	2022	Small molecules such as lopinavir and favipiravir significantly inhibit the activity of Mpro and RdRp in vitro.	favipiravir	38-49	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	88-92
33251975-4	2022	Small molecules such as lopinavir and favipiravir significantly inhibit the activity of Mpro and RdRp in vitro.	favipiravir	38-49	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	97-101
33251975-9	2022	Molecular interaction analyses have displayed that lopinavir and favipiravir analogues interact with the active site residues of Mpro and RdRp, respectively.	favipiravir	65-76	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	129-133
33251975-9	2022	Molecular interaction analyses have displayed that lopinavir and favipiravir analogues interact with the active site residues of Mpro and RdRp, respectively.	favipiravir	65-76	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	138-142
33050947-5	2020	INTERVENTION AND COMPARATOR: The first candidate antiviral is favipiravir Arm 1: Favipiravir 1800 mg favipiravir BD on Day 1 followed by 800 mg BD favipiravir for the next 13 days.	favipiravir	62-73	kallikrein related peptidase 4	Homo sapiens	74-79
33050947-5	2020	INTERVENTION AND COMPARATOR: The first candidate antiviral is favipiravir Arm 1: Favipiravir 1800 mg favipiravir BD on Day 1 followed by 800 mg BD favipiravir for the next 13 days.	favipiravir	81-92	kallikrein related peptidase 4	Homo sapiens	74-79
33050947-5	2020	INTERVENTION AND COMPARATOR: The first candidate antiviral is favipiravir Arm 1: Favipiravir 1800 mg favipiravir BD on Day 1 followed by 800 mg BD favipiravir for the next 13 days.	favipiravir	101-112	kallikrein related peptidase 4	Homo sapiens	74-79
33050947-5	2020	INTERVENTION AND COMPARATOR: The first candidate antiviral is favipiravir Arm 1: Favipiravir 1800 mg favipiravir BD on Day 1 followed by 800 mg BD favipiravir for the next 13 days.	favipiravir	101-112	kallikrein related peptidase 4	Homo sapiens	74-79
32783586-5	2021	The RNA dependent RNA polymerase (RdRp) protein was selected as the target protein as favipiravir inhibits this protein in the human body.	favipiravir	86-97	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	34-38
32783586-7	2021	Then, the inhibition properties of selected drug candidates and favipiravir were examined in detail against SARS-CoV-2 RdRp proteins.	favipiravir	64-75	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	119-123
32246834-4	2020	Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials.	favipiravir	0-11	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	53-57
32392072-6	2020	Furthermore, we demonstrate the binding poses of three viral RdRp inhibitors (Galidesivir, Favipiravir, and Penciclovir), which were recently reported to have clinical significance for SARS-CoV-2.	favipiravir	91-102	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	61-65
32536670-6	2020	Favipiravir and M1 act as moderate inhibitors of organic anion transporter 1 and 3 (OAT1 and OAT3), which are involved in uric acid excretion in the kidney.	favipiravir	0-11	solute carrier family 22 member 6	Homo sapiens	49-82
32536670-6	2020	Favipiravir and M1 act as moderate inhibitors of organic anion transporter 1 and 3 (OAT1 and OAT3), which are involved in uric acid excretion in the kidney.	favipiravir	0-11	solute carrier family 22 member 6	Homo sapiens	84-88
32536670-6	2020	Favipiravir and M1 act as moderate inhibitors of organic anion transporter 1 and 3 (OAT1 and OAT3), which are involved in uric acid excretion in the kidney.	favipiravir	0-11	solute carrier family 22 member 8	Homo sapiens	93-97
34835018-10	2021	Interestingly, Favipiravir strongly decreased the blood levels of the liver disease markers aspartate- and alanine aminotransferase in the pre- and concurrently treated MAYV-infected mice.	favipiravir	15-26	glutamic--pyruvic transaminase	Homo sapiens	107-131
31194854-9	2019	Moreover, administration of favipiravir as a prophylaxis or as post-exposure therapy three days after infection prevented BRBV-STL-induced mortality in immunocompromised Ifnar1-/- mice.	favipiravir	28-39	interferon (alpha and beta) receptor 1	Mus musculus	170-176
30385306-7	2018	Treatment of mice with favipiravir (150 mg/kg/dose, BID, oral gavage) significantly reduced viral load in blood and tissues and significantly delayed virus-induced disease.	favipiravir	23-34	BH3 interacting domain death agonist	Mus musculus	52-55
27881648-0	2017	Modeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with Favipiravir.	favipiravir	167-178	signal transducer and activator of transcription 2	Mesocricetus auratus	110-115
27881648-8	2017	We also show that SFTSV infection in STAT2 knockout (KO) hamsters is responsive to favipiravir treatment, which protected all animals from lethal disease and reduced serum and tissue viral loads by 3 to 6 orders of magnitude.	favipiravir	83-94	signal transducer and activator of transcription 2	Mesocricetus auratus	37-42
23907213-0	2013	Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir).	favipiravir	98-103	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	14-60
23907213-0	2013	Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir).	favipiravir	105-116	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	14-60
23907213-4	2013	We here demonstrate that human hypoxanthine guanine phosphoribosyltransferase (HGPRT) converts T-705 into its ribose-5"-monophosphate (RMP) prior to formation of T-705-RTP.	favipiravir	95-100	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	31-77
23907213-4	2013	We here demonstrate that human hypoxanthine guanine phosphoribosyltransferase (HGPRT) converts T-705 into its ribose-5"-monophosphate (RMP) prior to formation of T-705-RTP.	favipiravir	95-100	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	79-84
34873274-4	2021	Molecular docking indicated that favipiravir has similar binding affinities to SARS-CoV-2 and HCoV-NL63 RdRp with LibDock scores of 75 and 74, respectively.	favipiravir	33-44	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	104-108
31864069-6	2020	RESULTS: VA1 replication was inhibited 10-100-fold by both ribavirin (EC50 = 154 muM) and favipiravir (EC50 = 246 muM).	favipiravir	90-101	latexin	Homo sapiens	114-117
30741966-6	2019	In conclusion, application of PET to the evaluation of favipiravir has demonstrated the importance of dosing regimen on the distribution and tissue uptake and clearance of the molecule.	favipiravir	55-66	thyroid stimulating hormone receptor	Mus musculus	30-33
30741966-8	2019	Measurement of the tissue uptake of favipiravir as determined by PET may be a more important indicator of a compound"s potential efficacy than purely monitoring plasma parameters such as viremia and drug levels.	favipiravir	36-47	thyroid stimulating hormone receptor	Mus musculus	65-68
30365543-2	2018	Favipiravir was reported to be effective in the treatment of SFTSV infection in vivo in type I interferon receptor knockout (IFNAR-/-) mice at treatment dosages of both 60 mg/kg/day and 300 mg/kg/day for a duration of 5 days.	favipiravir	0-11	interferon (alpha and beta) receptor 1	Mus musculus	125-130
30365543-3	2018	In this study, the efficacy of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day against SFTSV infection in an IFNAR-/- mouse infection model was investigated.	favipiravir	31-42	interferon (alpha and beta) receptor 1	Mus musculus	119-124
30365543-12	2018	Similar to the literature-reported peritoneal administration of favipiravir at 300 mg/kg/day, the oral administration of favipiravir at dosages of 120 mg/kg/day and 200 mg/kg/day to IFNAR-/- mice infected with SFTSV was effective.	favipiravir	121-132	interferon (alpha and beta) receptor 1	Mus musculus	182-187
28105854-9	2017	In this study, T-705 showed the antiviral activity of reducing pulmonary viral load compared with oseltamivir, thereby suppressing the TNF-alpha production.	favipiravir	15-20	tumor necrosis factor	Mus musculus	135-144
27303697-8	2016	Intraperitoneal or oral administration of T-705 for 5 days to IFNAR(-/-) mice infected with lethal SFTSV significantly improved survival rates (100% survival) without causing body weight loss and reduced the viral load in the serum.	favipiravir	42-47	interferon (alpha and beta) receptor 1	Mus musculus	62-67
22022624-6	2011	Antiviral activity and reduced disease severity was evidenced by dramatic reductions in peak serum virus titers and AST concentrations in favipiravir-treated animals.	favipiravir	138-149	solute carrier family 17 member 5	Homo sapiens	116-119
33815808-8	2021	Aloe, azadirachtin, columbin, cirsilineol, nimbiol, nimbocinol and sage exhibited highest binding affinity and interacted with active sites of RdRp surpassing the ability of chloroquine, lamivudine, favipiravir and remdesivir to target the same.	favipiravir	199-210	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	143-147
34881025-5	2021	With a strong affinity toward the viral RNA-dependent RNA polymerase (RdRp), favipiravir could be a promising therapy against SARS-CoV-2, by targeting downstream viral RNA replication.	favipiravir	77-88	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	70-74
34717229-8	2021	The comparative analysis revealed that the selected compounds showed higher potential to be developed as RdRp-RNA inhibitors than antiviral medicines Remdesivir and Favipiravir.	favipiravir	165-176	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	105-109
34829734-7	2021	Similarly, marine terpenoids such as xiamycin (-9.3), thyrsiferol (-9.2), liouvilloside B (-8.9), liouvilloside A (-8.8), and stachyflin (-8.7) exhibited comparatively higher docking scores than the referral drug remdesivir (-7.4), and favipiravir (-5.7) against the target SARS-CoV-2-RdRp.	favipiravir	236-247	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	285-289
34247016-3	2021	Herein, I discovered and introduce a new pyrazine derivative, (E)-N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20), as the first potent SARS-CoV-2 RdRp inhibitor with very high selectivity (209- and 45-fold more potent than favipiravir and remdesivir, respectively).	favipiravir	254-265	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	177-181
34934766-9	2021	Wood"s lamp examination of the plasma taken from a patient after favipiravir"s first dose revealed the same luminescence as we saw on the nails.	favipiravir	65-76	lysosomal associated membrane protein 3	Homo sapiens	7-11
34339634-2	2021	Nucleotide analogs such as remdesivir and favipiravir are thought to interfere with the RNA replication by RdRp.	favipiravir	42-53	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	107-111
34339634-6	2021	The ligand recognition ability of RdRp decreased in the order of remdesivir, favipiravir, and ATP.	favipiravir	77-88	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	34-38
34126092-12	2021	In a COVID-19 trial, total adverse drug events (ADEs) were much lower in the Favipiravir (FPV) + IFN-alpha group compared with the LPV/RTV arm (P = 0.001).	favipiravir	77-88	interferon alpha 1	Homo sapiens	97-106
34409597-2	2021	Accumulation of mutations in SARS-CoV-2 RdRp may facilitate antigenic drift, generating favipiravir resistance.	favipiravir	88-99	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	40-44
34409597-3	2021	Focusing on the chain-termination mechanism utilized by favipiravir, we used high-throughput interface-based protein design to generate >100,000 designs of the favipiravir-binding site of RdRp and identify mutational hotspots.	favipiravir	56-67	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	188-192
34409597-3	2021	Focusing on the chain-termination mechanism utilized by favipiravir, we used high-throughput interface-based protein design to generate >100,000 designs of the favipiravir-binding site of RdRp and identify mutational hotspots.	favipiravir	160-171	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	188-192
34409597-4	2021	We identified several single-point mutants and designs having a sequence identity of 97-98% with wildtype RdRp, suggesting that SARS-CoV-2 can develop favipiravir resistance with few mutations.	favipiravir	151-162	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	106-110
34703696-6	2021	AST elevation was found, respectively, as 133 (29.3%), 32 (28.3%) (p=0.100), ALT elevation as 112 (24.7%), 35 (29.3%) (p=0.100) in the groups receiving and not receiving favipiravir.	favipiravir	170-181	solute carrier family 17 member 5	Homo sapiens	0-3
34552976-0	2021	Antiviral Effectivity of Favipiravir Against Peste Des Petits Ruminants Virus Is Mediated by the JAK/STAT and PI3K/AKT Pathways.	favipiravir	25-36	AKT serine/threonine kinase 1	Homo sapiens	115-118
34552976-7	2021	Furthermore, in favipiravir-treated cells, the expression of JAK1 and STAT1 was downregulated, whereas that of p-STAT1 was significantly upregulated.	favipiravir	16-27	Janus kinase 1	Homo sapiens	61-65
34552976-7	2021	Furthermore, in favipiravir-treated cells, the expression of JAK1 and STAT1 was downregulated, whereas that of p-STAT1 was significantly upregulated.	favipiravir	16-27	signal transducer and activator of transcription 1	Homo sapiens	70-75
34552976-7	2021	Furthermore, in favipiravir-treated cells, the expression of JAK1 and STAT1 was downregulated, whereas that of p-STAT1 was significantly upregulated.	favipiravir	16-27	signal transducer and activator of transcription 1	Homo sapiens	113-118
34552976-9	2021	Moreover, with favipiravir treatment, the expression of PI3K and p-AKT and the p-AKT/AKT ratio were significantly decreased, whereas the expression of AKT was noticeably upregulated.	favipiravir	15-26	AKT serine/threonine kinase 1	Homo sapiens	67-70
34552976-9	2021	Moreover, with favipiravir treatment, the expression of PI3K and p-AKT and the p-AKT/AKT ratio were significantly decreased, whereas the expression of AKT was noticeably upregulated.	favipiravir	15-26	AKT serine/threonine kinase 1	Homo sapiens	81-84
34552976-9	2021	Moreover, with favipiravir treatment, the expression of PI3K and p-AKT and the p-AKT/AKT ratio were significantly decreased, whereas the expression of AKT was noticeably upregulated.	favipiravir	15-26	AKT serine/threonine kinase 1	Homo sapiens	85-88
34552976-9	2021	Moreover, with favipiravir treatment, the expression of PI3K and p-AKT and the p-AKT/AKT ratio were significantly decreased, whereas the expression of AKT was noticeably upregulated.	favipiravir	15-26	AKT serine/threonine kinase 1	Homo sapiens	151-154
34552976-10	2021	The expression of GSK3, NF-kappaB p65, p-NF-kappaB p65, and BAD was also increased with favipiravir treatment, while the expression of CREB, p-CREB, p-GSK3, and Bcl-2 was slightly decreased.	favipiravir	88-99	nuclear factor kappa B subunit 1	Homo sapiens	24-33
34552976-10	2021	The expression of GSK3, NF-kappaB p65, p-NF-kappaB p65, and BAD was also increased with favipiravir treatment, while the expression of CREB, p-CREB, p-GSK3, and Bcl-2 was slightly decreased.	favipiravir	88-99	RELA proto-oncogene, NF-kB subunit	Homo sapiens	34-37
34552976-10	2021	The expression of GSK3, NF-kappaB p65, p-NF-kappaB p65, and BAD was also increased with favipiravir treatment, while the expression of CREB, p-CREB, p-GSK3, and Bcl-2 was slightly decreased.	favipiravir	88-99	RELA proto-oncogene, NF-kB subunit	Homo sapiens	41-54
34552976-10	2021	The expression of GSK3, NF-kappaB p65, p-NF-kappaB p65, and BAD was also increased with favipiravir treatment, while the expression of CREB, p-CREB, p-GSK3, and Bcl-2 was slightly decreased.	favipiravir	88-99	cAMP responsive element binding protein 1	Homo sapiens	135-139
34552976-10	2021	The expression of GSK3, NF-kappaB p65, p-NF-kappaB p65, and BAD was also increased with favipiravir treatment, while the expression of CREB, p-CREB, p-GSK3, and Bcl-2 was slightly decreased.	favipiravir	88-99	cAMP responsive element binding protein 1	Homo sapiens	143-147
34552976-10	2021	The expression of GSK3, NF-kappaB p65, p-NF-kappaB p65, and BAD was also increased with favipiravir treatment, while the expression of CREB, p-CREB, p-GSK3, and Bcl-2 was slightly decreased.	favipiravir	88-99	BCL2 apoptosis regulator	Homo sapiens	161-166
34552976-11	2021	In addition, all the p-GSK3/GSK3, p-CREB/CREB, p-NF-kappaB/NF-kappaB, and p-BAD/BAD ratios were significantly reduced in favipiravir-treated cells.	favipiravir	121-132	cAMP responsive element binding protein 1	Homo sapiens	36-40
34552976-11	2021	In addition, all the p-GSK3/GSK3, p-CREB/CREB, p-NF-kappaB/NF-kappaB, and p-BAD/BAD ratios were significantly reduced in favipiravir-treated cells.	favipiravir	121-132	cAMP responsive element binding protein 1	Homo sapiens	41-45
34552976-11	2021	In addition, all the p-GSK3/GSK3, p-CREB/CREB, p-NF-kappaB/NF-kappaB, and p-BAD/BAD ratios were significantly reduced in favipiravir-treated cells.	favipiravir	121-132	nuclear factor kappa B subunit 1	Homo sapiens	49-58
34552976-11	2021	In addition, all the p-GSK3/GSK3, p-CREB/CREB, p-NF-kappaB/NF-kappaB, and p-BAD/BAD ratios were significantly reduced in favipiravir-treated cells.	favipiravir	121-132	nuclear factor kappa B subunit 1	Homo sapiens	59-68
34552976-12	2021	These results implied that the antiviral effectivity of favipiravir against PPRV is mediated by the JAK/STAT and PI3K/AKT pathways and that favipiravir has potential for use as an effective antiviral agent against PPRV.	favipiravir	56-67	AKT serine/threonine kinase 1	Homo sapiens	118-121
34061908-2	2021	We previously described a favipiravir resistant influenza A virus generated by in vitro passage in presence of drug with two mutations: K229R in PB1, which conferred resistance at a cost to polymerase activity, and P653L in PA, which compensated for the cost of polymerase activity.	favipiravir	26-37	polybromo 1	Homo sapiens	145-148
34255596-10	2022	DISCUSSION: Favipiravir may inhibit methotrexate elimination by inhibiting aldehyde oxidase and its sequential use may cause hepatotoxicity in this case.	favipiravir	12-23	aldehyde oxidase 1	Homo sapiens	75-91
34372594-11	2021	Finally, favipiravir treatment fully protected STAT-1 KO mice from lethal SUDV challenge, suggesting that this may be an appropriate small animal model to screen anti-SUDV countermeasures.	favipiravir	9-20	signal transducer and activator of transcription 1	Mus musculus	47-53
34072604-0	2021	Favipiravir (T-705) Protects IFNAR-/- Mice against Lethal Zika Virus Infection in a Sex-Dependent Manner.	favipiravir	0-11	interferon (alpha and beta) receptor 1	Mus musculus	29-34
34136511-6	2021	In this study, we showed three bioactive molecules from tea (epicatechin-3,5-di-O-gallate, epigallocatechin-3,5-di-O-gallate, and epigallocatechin-3,4-di-O-gallate) that showed better interaction with critical residues present at the catalytic center and the NTP entry channel of RdRp than antiviral drugs Remdesivir and Favipiravir.	favipiravir	321-332	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	280-284
34072604-0	2021	Favipiravir (T-705) Protects IFNAR-/- Mice against Lethal Zika Virus Infection in a Sex-Dependent Manner.	favipiravir	13-18	interferon (alpha and beta) receptor 1	Mus musculus	29-34
34072604-5	2021	Testing in IFNAR-/- mice revealed that daily treatments of favipiravir were sufficient to provide protection against lethal ZIKV challenge in a dose-dependent manner but did not completely abrogate disease.	favipiravir	59-70	interferon (alpha and beta) receptor 1	Mus musculus	11-16
35185356-9	2022	RdRp inhibitors, such as remdesivir (an anti-Ebola virus experimental drug) and favipiravir (an anti-influenza drug), inhibit RdRp and thus slow the progression of COVID-19 and associated clinical symptoms, as well as significantly shorten recovery time.	favipiravir	80-91	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	0-4
35608787-0	2022	A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.	favipiravir	45-56	hexokinase 1	Homo sapiens	20-30
35608787-2	2022	Favipiravir and Molnupiravir exhibited novel hexokinase inhibition and we discuss advantages of this property in their COVID-19 inhibition potential.	favipiravir	0-11	hexokinase 1	Homo sapiens	45-55
35608787-5	2022	We observed potent human hexokinase inhibiting potential of Favipiravir (50%) as against 4% and merely 0.3% hexokinase inhibition with Molnupiravir and 2 Deoxy D glucose at 0.1 mM concentration supported by molecular docking studies.	favipiravir	60-71	hexokinase 1	Homo sapiens	25-35
35608787-6	2022	CONCLUSION: Favipiravir could continue to be part of the COVID-19 treatment regimen due to its resistance to host esterases, hexokinase inhibition potential and proven safety through human trials.	favipiravir	12-23	hexokinase 1	Homo sapiens	125-135
35628472-7	2022	Favipiravir, hydroxychloroquine, lopinavir, and the combination of lopinavir with ritonavir were found to inhibit pannexin1 channel activity without affecting pannexin1 protein or mRNA levels.	favipiravir	0-11	pannexin 1	Homo sapiens	114-123
35185356-9	2022	RdRp inhibitors, such as remdesivir (an anti-Ebola virus experimental drug) and favipiravir (an anti-influenza drug), inhibit RdRp and thus slow the progression of COVID-19 and associated clinical symptoms, as well as significantly shorten recovery time.	favipiravir	80-91	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	126-130
35430987-8	2022	Favipiravir is effective against SARS-CoV-2 infection through inhibition of RdRp.	favipiravir	0-11	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	76-80
35450509-7	2022	Favipiravir administration caused apoptotic cell death (Caspase-3 and Bcl-2), inflammation (NF-kappaB and IL-6), and a decrease in renal reabsorption (AQP2) levels.	favipiravir	0-11	caspase 3	Rattus norvegicus	49-65
35450509-7	2022	Favipiravir administration caused apoptotic cell death (Caspase-3 and Bcl-2), inflammation (NF-kappaB and IL-6), and a decrease in renal reabsorption (AQP2) levels.	favipiravir	0-11	BCL2, apoptosis regulator	Rattus norvegicus	70-75
35450509-7	2022	Favipiravir administration caused apoptotic cell death (Caspase-3 and Bcl-2), inflammation (NF-kappaB and IL-6), and a decrease in renal reabsorption (AQP2) levels.	favipiravir	0-11	interleukin 6	Rattus norvegicus	106-110
35450509-7	2022	Favipiravir administration caused apoptotic cell death (Caspase-3 and Bcl-2), inflammation (NF-kappaB and IL-6), and a decrease in renal reabsorption (AQP2) levels.	favipiravir	0-11	aquaporin 2	Rattus norvegicus	151-155
35215932-4	2022	Thus, to clarify the detailed molecular interactions between favipiravir and the RNA-dependent RNA polymerase (RdRp) of HMPV, RSV, MuV, MeV, and influenza virus, we performed in silico studies using authentic bioinformatics technologies.	favipiravir	61-72	RNA dependent RNA polymerase	Human metapneumovirus	81-109
35225067-2	2022	In this article, we present two patients diagnosed with anaplastic lymphoma kinase (ALK) + non-small cell lung adenocarcinoma (NSCL CA), infected with COVID-19, who had a previous multi-line therapy with Brigatinib and Lorlatinib, and received Favipiravir for their current infection.	favipiravir	244-255	ALK receptor tyrosine kinase	Homo sapiens	56-82
35225067-2	2022	In this article, we present two patients diagnosed with anaplastic lymphoma kinase (ALK) + non-small cell lung adenocarcinoma (NSCL CA), infected with COVID-19, who had a previous multi-line therapy with Brigatinib and Lorlatinib, and received Favipiravir for their current infection.	favipiravir	244-255	ALK receptor tyrosine kinase	Homo sapiens	84-87
35225067-7	2022	DISCUSSION: To our knowledge, these are the only reported cases diagnosed as ALK ( + ) NSCL CA who received favipiravir because of COVID-19 while using TKI, and both patients recovered completely without any side effects.	favipiravir	108-119	ALK receptor tyrosine kinase	Homo sapiens	77-80
35599639-8	2022	Results: Favipiravir increased the levels of RANKL and caspase-3 expression but decreased BMP-2 and ALP levels in a dose-dependent manner.	favipiravir	9-20	TNF superfamily member 11	Rattus norvegicus	45-50
35599639-8	2022	Results: Favipiravir increased the levels of RANKL and caspase-3 expression but decreased BMP-2 and ALP levels in a dose-dependent manner.	favipiravir	9-20	caspase 3	Rattus norvegicus	55-64
35599639-8	2022	Results: Favipiravir increased the levels of RANKL and caspase-3 expression but decreased BMP-2 and ALP levels in a dose-dependent manner.	favipiravir	9-20	bone morphogenetic protein 2	Rattus norvegicus	90-95